Want to join the conversation?
$GILD 2Q15 Call: 83% of genotype 1 patients have direct access to Harvoni, a percentage that has remained stable since 1Q15. In Europe, hepatitis C revenue was more than $1.1Bil, with over 30,000 estimated new patient starts. Saw particularly high patient initiations in Spain, Italy and Portugal during the quarter.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.